

Publications

2011

1. Cheng C, Pan L, Dimitrakopoulou-Strauss A, Schafer M, Wangler C, Wangler B, Haberkorn U, Strauss LG. Comparison between ^{68}Ga -bombesin (^{68}Ga -BZH3) and the cRGD tetramer ^{68}Ga -RGD4 studies in an experimental nude rat model with a neuroendocrine pancreatic tumor cell line. *EJNMMI Res.* 2011
2. Dimitrakopoulou-Strauss A, Seiz M, Tuettenberg J, Schmieder K, Eisenhut M, Haberkorn U, Strauss LG. Pharmacokinetic studies of ^{68}Ga -labeled Bombesin (^{68}Ga -BZH3) and ^{18}F -FDG PET in patients with recurrent gliomas and comparison to grading: preliminary results. *Clin Nucl Med.* 2011 Feb;36(2):101-8.
3. Mühlhausen U, Komljenovic D, Bretsch M, Leotta K, Eisenhut M, Semmler W, Bäuerle T. A novel PET tracer for the imaging of $\alpha\beta 3$ and $\alpha\beta 5$ integrins in experimental breast cancer bone metastases. *Contrast Media Mol Imaging.* 2011 6:413-20.
4. Haberkorn U, Markert A, Eisenhut M, Mier W, Altmann A. Development of molecular techniques for imaging and treatment of tumors. *Q J Nucl Med Mol Imaging.* 2011 55:655-70.
5. Hennrich U, Seyler L, Schäfer M, Bauder-Wüst U, Eisenhut M, Semmler W, Bäuerle T. Synthesis and in vitro evaluation of (^{68}Ga)-DOTA-4-FBn-TN14003, a novel tracer for the imaging of CXCR4 expression. *Bioorg Med Chem.* 2012
6. Müller A, Zitzmann-Kolbe S, Böhnke N, Dewi-Wülfing P, Oltmanns D, Eisenhut M, Bauder-Wuest U. Compounds for imaging apoptotic cell death. *WO2011/073137 A2*
7. Wängler C, Schäfer M, Schirmacher R, Bartenstein P, Wängler B. DOTA derivatives for site-specific biomolecule-modification via click chemistry: synthesis and comparison of reaction characteristics. *Bioorg Med Chem.* 2011 Jun 15;19(12):3864-74

2010

1. Altmann A, Eisenhut M, Bauder-Wüst U, Markert A, Askoxylakis V, Hess-Stumpp H, Haberkorn U. Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275. *Eur J Nucl Med Mol Imaging.* 2010 37 2286–2297.
2. Boy RG, Mier W, Nothelfer EM, Altmann A, Eisenhut M, Kolmar H, Tomaszowski M, Krämer S, Haberkorn U. Sunflower Trypsin Inhibitor 1 Derivatives as Molecular Scaffolds for the Development of Novel Peptidic Radiopharmaceuticals. *Mol Imaging Biol.* 2010: 12, 377-85.
3. Eder M, Knackmuss S, Le Gall F, Reusch U, Rybin V, Little M, Haberkorn U, Mier W, Eisenhut M. ^{68}Ga -labelled recombinant antibody variants for immuno-PET imaging of solid tumours. *Eur J Nucl Med Mol Imaging.* 2010: 37, 1397-1407.
4. Eder M, Krivoshein AV, Backer M, Backer JM, Haberkorn U, Eisenhut M. ScVEGF-PEG-HBED-CC and scVEGF-PEG-NOTA conjugates: comparison of easy-to-label recombinant proteins for [^{68}Ga]PET imaging of VEGF receptors in angiogenic vasculature. *Nucl Med Biol.* 2010: 37, 405-12.

5. Jahn M., Radchenko V., Filosofov D. V., Hauser H., Eisenhut M., Rösch F. and Jennewein M. Separation and purification of no-carrier-added arsenic from bulk amounts of germanium for use in radiopharmaceutical labelling. *Radiochimica Acta* 2010 98 807-812.
6. Kratochwil C, Giesel FL, López-Benítez R, Schimpfky N, Kunze K, Eisenhut M, Kauczor HU, Haberkorn U. Intraindividual comparison of selective arterial versus venous ⁶⁸Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors. *Clin Cancer Res.* 2010; 16, 2899-905.
7. Kubas H, Schäfer M, Bauder-Wüst U, Eder M, Oltmanns D, Haberkorn U, Mier W, Eisenhut M. Multivalent Cyclic RGD-Ligands: Influence of Linker Lengths on Receptor Binding. *Nuclear Medicine and Biology* 37 (2010) 885–891
8. Nissen F, Kraft TE, Ruppert T, Eisenhut M, Haberkorn U, Mier W. Hot or not — the influence of elevated temperature and microwave irradiation on the solid phase synthesis of an affibody. *Tetrahedron Letters* 2010 51 6216–6219
9. Sarko D, Beijer B, Boy RG, Nothelfer EM, Leotta K, Eisenhut M, Altmann A, Haberkorn U, Mier W. The Pharmacokinetics of Cell-Penetrating Peptides. *Mol Pharm.* 2010, 7, 2224–2231.
10. Wängler C, Maschauer S, Prante O, Schäfer M, Schirmacher R, Bartenstein P, Eisenhut M, Wängler B. Multimerization of cRGD Peptides by Click Chemistry: Synthetic Strategies, Chemical Limitations, and Influence on Biological Properties. *Chembiochem.* 2010:11, 2168-81
11. Zitzmann-Kolbe S, Oltmanns D, Eisenhut M, Bauder-Wuest U. Cyclic polyamines for binding phosphatidylserine. EP 2 149 567 A1

2009

1. Haberkorn,U., Eisenhut,M., Altmann,A., Mier,W.: Molecular endoradiotherapy of cancer. *Minerva Biotechnologica* 2009: 21, 5-19.
2. Kiessling,F., Huppert,J., Zhang,C.F., Jayapaul,J., Zwick,S., Woenne,E.C., Mueller,M.M., Zentgraf,H., Eisenhut,M., Addadi,Y., Neeman,M., Semmler,W.: RGD-labeled USPIO Inhibits Adhesion and Endocytotic Activity of alpha(v)beta(3)-Integrin-expressing Glioma Cells and Only Accumulates in the Vascular Tumor Compartment. *Radiology* 2009: 253, 462-469.
3. Nothelfer EM, Zitzmann-Kolbe S, Garcia-Boy R, Krämer S, Herold-Mende C, Altmann A, Eisenhut M, Mier W, Haberkorn U. Identification and Characterization of a Peptide with Affinity to Head and Neck Cancer. *J Nucl Med.* 2009: 50, 426-34.
4. Oltmanns D, Eisenhut M, Mier W, Haberkorn U. Benzamides as melanotropic carriers for radioisotopes, metals, cytotoxic agents and as enzyme inhibitors. *Curr Med Chem.* 2009: 16,2086-94.
5. Zoller,F., Eisenhut,M., Haberkorn,U., Mier,W.: Endoradiotherapy in cancer treatment - Basic concepts and future trends. *European Journal of Pharmacology* 2009: 625, 55-62.

2008

1. Boy RG, Knapp EM, Eisenhut M, Haberkorn U, Mier W. Enzymes/transporters. *Handb Exp Pharmacol*. 2008;(185 Pt 2):131-43.
2. Eder M, Wängler B, Knackmuss S, Legall F, Little M, Haberkorn U, Mier W, Eisenhut M. Tetrafluorophenolate of HBED-CC: a versatile conjugation agent for (68)Ga-labeled small recombinant antibodies. *Eur J Nucl Med Mol Imaging*. 2008 Oct;35(10):1878-86.
3. Eisenhut M. Strahlenanwendung und Strahlenforschung in Deutschland – Einschätzung durch die Arbeitsgemeinschaft Radiochemie/Radiopharmazie. *Nova Acta Leopoldina NF* 2008, 96, 165-167.
4. Eisenhut M, W. Mier, U. Haberkorn. Apoptosis. In *Encyclopedia of Diagnostic Imaging* A.L. Baert (Ed.). Springer Verlag, Berlin, Heidelberg. 2008, 121 – 125.
5. Eisenhut M., W. Mier. Radiochemie, Radiopharmazie. In *Nuklearmedizin* (T. Kuwert et al. Eds.) G. Thieme Verlag, Stuttgart. 2008. pp 83-101
6. Haberkorn U, Eisenhut M, Altmann A, Mier W. Endoradiotherapy with peptides - status and future development. *Curr Med Chem*. 2008;15(3):219-34.
7. Seiz M, Dimitrakopoulou-Strauss A, Schubert GA, Weinmann C, Strauss LG, Eisenhut M, Tuettenberg J. Differentiation between malignant transformation and tumour recurrence by (68)Ga-bombesin and (18)F-FDG-PET, in patients with low grade gliomas. *Hell J Nucl Med*. 2008 Sep-Dec;11(3):149-52.
8. Wängler C, Wängler B, Eisenhut M, Haberkorn U, Mier W. Improved syntheses and applicability of different DOTA building blocks for multiply derivatized scaffolds. *Bioorg Med Chem*. 2008 Mar 1;16(5):2606-16.
9. Wängler C, Moldenhauer G, Saffrich R, Knapp EM, Beijer B, Schnölzer M, Wängler B, Eisenhut M, Haberkorn U, Mier W. PAMAM Structure-Based Multifunctional Fluorescent Conjugates for Improved Fluorescent Labelling of Biomacromolecules. *Chemistry*. 2008;14(27):8116-30.
10. Wängler C, Moldenhauer G, Eisenhut M, Haberkorn U, Mier W. Antibody-dendrimer conjugates: the number, not the size of the dendrimers, determines the immunoreactivity. *Bioconjug Chem*. 2008 Apr;19(4):813-20.
11. Windhorst AD, Klein PJ, Eisenbarth J, Oeser T, Kruijer PS, Eisenhut M. 3'-Sulfonylestere of 2,5'-anhydro-1-(2-deoxy-beta-d-threo-pentofuranosyl)thymine as precursors for the synthesis of [(18)F]FLT: syntheses and radiofluorination trials. *Nucl Med Biol*. 2008 May;35(4):413-23.
12. Wolf M. Influence of matrigel on biodistribution studies in cancer research. *Die Pharmazie* 2008, 63, 43-8.

2007

1. Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, Schilling T, Haufe S, Herrmann T, Haberkorn U. Comparison of ⁶⁸Ga-DOTATOC PET and ¹¹¹In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. *Eur J Nucl Med Mol Imaging*. 2007 Oct;34(10):1617-26.
2. Dimitrakopoulou-Strauss A, Hoffmann M, Bergner R, Uppenkamp M, Eisenhut M, Pan L, Haberkorn U, Strauss LG. Prediction of Short-term Survival in Patients with Advanced Non-small Cell Lung Cancer Following Chemotherapy Based on 2-Deoxy-2-[¹⁸F]fluoro-D: -glucose-Positron Emission Tomography: A Feasibility Study. *Mol Imaging Biol* 2007;9:308-17.
3. Dimitrakopoulou-Strauss A, Hohenberger P, Haberkorn U, Mäcke HR, Eisenhut M, Strauss LG. ⁶⁸Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with ¹⁸F-FDG. *J Nucl Med*. 2007 Aug;48(8):1245-50.
4. Graham K, Wang Q, Garcia Boy R, Eisenhut M, Haberkorn U, Mier W. Synthesis and evaluation of intercalating somatostatin receptor binding peptide conjugates for endoradiotherapy. *J Pharm Sci*. 2007;10(2):286s-297s.
5. Haberkorn U, Altmann A, Mier W, Eisenhut M. Molecular imaging of tumor metabolism and apoptosis. *Ernst Schering Found Symp Proc*. 2007;(4):125-52. Review.
6. Haberkorn U, Hoffend J, Schmidt K, Altmann A, Bonaterra GA, Dimitrakopoulou-Strauss A, Strauss LG, Eisenhut M, Kinscherf R. Changes in glucose metabolism and gene expression after transfer of anti-angiogenic genes in rat hepatoma. *Eur J Nucl Med Mol Imaging*. 2007 Dec;34(12):2011-23.
7. Kasper B, Egerer G, Gronkowski M, Haufe S, Lehnert T, Eisenhut M, Mechttersheimer G, Ho AD, Haberkorn U. Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET. *Leuk Lymphoma*. 2007 Apr;48(4):746-53.
8. Mier W, Zitzmann S, Krämer S, Reed J, Knapp EM, Altmann A, Eisenhut M, Haberkorn U. Influence of chelate conjugation on a newly identified tumor-targeting peptide. *J Nucl Med*. 2007 Sep;48(9):1545-52.
9. Schirrmacher E, Wängler B, Cypryk M, Bradtmöller G, Schäfer M, Eisenhut M, Jurkschat K, Schirrmacher R. Synthesis of p-(Di-tert-butyl[¹⁸F]fluorosilyl)benzaldehyde ([¹⁸F]SiFA-A) with high specific activity by isotopic exchange: a convenient labeling synthon for the ¹⁸F-labeling of N-amino-oxy derivatized peptides. *Bioconjug Chem*. 2007 Nov-Dec;18(6):2085-9.
10. Schirrmacher R, Wängler C, Schirrmacher E (2007) Recent developments and trends in ¹⁸F-radiochemistry: Syntheses and Applications. *Mini-Reviews in Organic Chemistry* 4, 317-329.
11. Wängler Carmen, Inga Buchmann, Michael Eisenhut, Uwe Haberkorn and Walter Mier. Radiolabeled peptides and proteins in cancer therapy. *Protein, Peptide Letters* 2007, 14: 273-9.
12. Wolf M, Bauder-Wust U, Eskerski H, Bauer C, Eisenhut M. Role of acidic cell organelles in the higher nonmelanoma retention of melanoma markers based on N-(2-dialkylaminoethyl)benzamides and the cytotoxicity of alkylating benzamides. *Melanoma Res*. 2007 Apr;17(2):61-73.

13. Wolf M, Hull WE, Mier W, Heiland S, Bauder-Wüst U, Kinscherf R, Haberkorn U, Eisenhut M. Polyamine-substituted Gd-DTPA: a new class of intracellular contrast agents for magnetic resonance imaging of tumors. *J. Med. Chem.* 2007, 50, 139-148.
14. Zhang C, Wangler B, Morgenstern B, Zentgraf H, Eisenhut M, Untenecker H, Kruger R, Huss R, Seliger C, Semmler W, Kiessling F. Silica- and alkoxy silane-coated ultrasmall superparamagnetic iron oxide particles: a promising tool to label cells for magnetic resonance imaging. *Langmuir.* 2007 Jan 30;23(3):1427-34.
15. Zhang Chunfu, Manfred Jugold, Eva C. Woenne, Twan Lammers, Bernd Morgenstern, Margareta M. Mueller, Hanswalter Zentgraf, Michael Bock, Michael Eisenhut, Wolfhard Semmler, and Fabian Kiessling. Specific Targeting of Tumor Angiogenesis by RGD-Conjugated Ultrasmall Superparamagnetic Iron Oxide Particles Using a Clinical 1.5-T Magnetic Resonance Scanner. *Cancer Res* 2007; 67: 1555-1562.
16. Zhang H, Schuhmacher J, Waser B, Wild D, Eisenhut M, Reubi JC, Maecke HR. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. *Eur J Nucl Med Mol Imaging.* 2007, 34, 1198-1208.
17. Zitzmann S, Kramer S, Mier W, Hebling U, Altmann A, Rother A, Berndorff D, Eisenhut M, Haberkorn U. Identification and Evaluation of a New Tumor Cell-Binding Peptide, FROP-1. *J Nucl Med.* 2007 Jun;48(6):965-972.

2006

1. Askoxylakis V, Mier W, Zitzmann S, Ehemann V, Zhang J, Kramer S, Beck C, Schwab M, Eisenhut M, Haberkorn U. Characterization and development of a peptide (p160) with affinity for neuroblastoma cells. *J Nucl Med.* 2006 Jun;47(6):981-8.
2. Bauder-Wüst U, Eisenhut M, Eskerski H, Haberkorn U, Heiland S, Hull WE, Kinscherf R, Mier W, Pipkorn R, Wolf M. »Polyamine-substituted ligands for use as contrast agents«, US-Patent 2006 (patent application submitted).
3. Calderon Sanchez O., A. Mohammed, C. Bauer, M. Wolf, W. Mier, U. Haberkorn, R. Mocoelo and M. Eisenhut. ^{99m}Tc Complexes with Activated Ester Functions; Ligands comprising a 3,4-Diaminobenzoate Backbone. *Nuclear Medicine and Biology* 2006; 33:381–390
4. Dervillez X, Huther A, Schuhmacher J, Griesinger C, Cohen JH, von Laer D, Dietrich U. Stable expression of soluble therapeutic peptides in eukaryotic cells by multimerisation: application to the HIV-1 fusion inhibitory peptide C46. *ChemMedChem.* 2006 Mar;1(3):330-9.
5. Dimitrakopoulou-Strauss A, Georgoulas V, Eisenhut M, Herth F, Koukouraki S, Macke HR, Haberkorn U, Strauss LG. Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using (68)Ga-DOTATOC PET and comparison with (18)F-FDG PET. *Eur J Nucl Med Mol Imaging.* 2006, 33: 823-830
6. Eisenbarth J, Martin M, Wagner-Utermann U, Eisenhut M. Markable compounds for easy synthesis of 3'-[¹⁸F]fluoro-3'-deoxynucleotides, and method for their production US 7,145,000 B2 (05.12.2006)
7. Eisenhut M., U. Haberkorn. Invited perspective: The molecular position of radiolabels and its impact on functional integrity of proteins. *J Nucl Med* 2006 47: 1400-1402.

8. Henze M., Özdemir-Sahin N., Hipp P., Mier W., Eisenhut M., Debus J., Haberkorn U. Comparison of diagnostic accuracy of 18F-FDG PET, 123I-IMT- and 99mTc-MIBI SPECT Evaluation of tumour progression in irradiated low grade astrocytomas. *Nuklearmedizin* 2006 45, 49–56.
9. Hoffend Johannes, Irimi Xenodimitropoulou, Walter Mier, Ashour Mohammed, Michael Eisenhut, Dirk Schadendorf, Helmut Näher, Michael Flesch, Uwe Haberkorn. Iod-123-IMBA Szintigraphie bei metastasiertem malignem Melanom. *Nuklearmedizin* 2006, submitted.
10. Kiessling F, Heilmann M, Lammers T, Ulbrich K, Subr V, Peschke P, Waengler B, Mier W, Schrenk HH, Bock M, Schad L, Semmler W. Synthesis and characterization of HE-24.8: a polymeric contrast agent for magnetic resonance angiography. *Bioconjug Chem.* 2006 Jan-Feb;17(1):42-51.
11. Koukouraki S, Strauss LG, Georgoulas V, Eisenhut M, Haberkorn U, Dimitrakopoulou-Strauss A. Comparison of the pharmacokinetics of (68)Ga-DOTATOC and [(18)F]FDG in patients with metastatic neuroendocrine tumours scheduled for (90)Y-DOTATOC therapy. *Eur J Nucl Med Mol Imaging.* 2006 33 1115
12. Koukouraki S, Strauss LG, Georgoulas V, Schuhmacher J, Haberkorn U, Karkavitsas N, Dimitrakopoulou-Strauss A. Evaluation of the pharmacokinetics of (68)Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for (90)Y-DOTATOC therapy. *Eur J Nucl Med Mol Imaging.* 2006 Apr;33(4):460-6.
13. Kunz P, Hoffend J, Altmann A, Strauss LG, Dimitrakopoulou-Strauss A, Koczan D, Eisenhut M, Bonaterra GA, Dengler TJ, Mier W, Haberkorn U, Kinscherf R. Angiopoietin-2-overexpression in Morris hepatoma results in increased tumor perfusion and induction of critical angiogenesis-promoting genes. *J Nucl Med* 2006;47:1515-1524.
14. Schirmacher R, Bradtmoller G, Schirmacher E, Thews O, Tillmanns J, Siessmeier T, Buchholz HG, Bartenstein P, Wängler B, Niemeyer CM, Jurkschat K. (18)F-Labeling of Peptides by means of an Organosilicon-Based Fluoride Acceptor. *Angew Chem Int Ed Engl.* 2006 Aug 3; [Epub ahead of print].
15. Mier Walter, Uwe Haberkorn and Michael Eisenhut. Receptor Binding Peptides for Receptor Mediated Endoradiotherapy in Oncology, in *Signalling Molecules as Targets in Cancer Therapy*. Editors: Vittorio de Franciscis, Laura Cerchia, Bertrand Tavitian, Nova Science Publishers, Inc. pp. 215-226, 2006
16. Schmidt K, Hoffend J, Altmann A, Strauss LG, Dimitrakopoulou-Strauss A, Engelhardt B, Koczan D, Peter J, Dengler TJ, Mier W, Eisenhut M, Haberkorn U, Kinscherf R. Angiostatin Overexpression in Morris Hepatoma Results in Decreased Tumor Growth but Increased Perfusion and Vascularization. *J Nucl Med.* 2006 Mar;47(3):543-551.
17. Schmidt Kerstin, Johannes Hoffend, Annette Altmann, Fabian Kiessling, Ludwig Strauss, Dirk Koczan, Walter Mier, Michael Eisenhut, Ralf Kinscherf, and Uwe Haberkorn Troponin I Overexpression Inhibits Tumor Growth, Perfusion, and Vascularization of Morris Hepatoma. *J Nucl Med* 2006 47: 1506-1514.
18. Wängler B., C. Beck, U. Wagner-Utermann, E. Schirmacher, C. Bauer, F. Rösch, R. Schirmacher, M. Eisenhut. Application of tris-allyl-DOTA in the preparation of DOTA-peptide conjugates. *Tetrahedron Letters* 47 (2006) 5985–5988.

19. Wolf M, Bauder-Wüst U, Pipkorn R, Eskerski H, Eisenhut M. Fluorophor-labeled spermidine derivatives as fluorescent markers in optical tumor imaging. *Bioorg Med Chem Lett* 2006;16:3193-6..
20. Wolf M, Eskerski H, Bauder-Wüst U, Haberkorn U, Eisenhut M. Alkylating benzamides with melanoma cytotoxicity: Experimental chemotherapy in a mouse melanoma model. *Melanoma Res.* 2006 Dec;16(6):487-96.

2005

1. Altmann A, Schulz RB, Glensch G, Eskerski H, Zitzmann S, Eisenhut M, Haberkorn U. Imaging of functional protein-protein interaction by transfer of the Pax8 and TTF-1 transcription factors genes. *J Nucl Med.* 2005 May;46(5):831-9.
2. Askoxylakis V, Zitzmann S, Mier W, Graham K, Kramer S, von Wegner F, Fink RH, Schwab M, Eisenhut M, Haberkorn U. Preclinical evaluation of the breast cancer cell-binding peptide, p160. *Clin Cancer Res.* 2005 Sep 15;11(18):6705-12.
3. Bauer C, Bauder-Wuest U, Mier W, Haberkorn U, Eisenhut M. Investigation of ¹³¹I labelled Peptides as Caspases Substrates for Apoptosis Imaging. *J Nucl Med* 2005;46:1066-1074.
4. Cermáková M., S. Krämer, J. Hoffend, M. Eisenhut, U. Haberkorn, W. Mier. Lipophilic derivatives of octreotate for the tumor selective transfection with liposomes. Proceedings of the 28th European Peptide Symposium (Eds. Flegel, Fridkin, Gilon and Slaninova) Kenes International, 2005, 585-6.
5. Fiehn C, Wunder A, Krienke S, Max R, Ho AD, Moehler T. Lack of evidence for inhibition of angiogenesis as a central mechanism of the antiarthritic effect of methotrexate. *Rheumatol Int.* 2005 Mar;25(2):108-13. Epub 2003 Nov 15.
6. Graham K.A.N., Q. Wang, U. Haberkorn, M. Eisenhut, W. Mier. Synthesis and evaluation of intercalating peptide conjugates for the endoradiotherapy. Proceedings of the 28th European Peptide Symposium (Eds. Flegel, Fridkin, Gilon and Slaninova) Kenes International, 2005, 301-2.
7. Grimm J, Hengerer A, and Wunder A. Molecular imaging. In: *Imaging Systems for Medical Diagnostics. Fundamentals, technical solutions and applications for systems applying ionization radiation, nuclear magnetic resonance and ultrasound.* Opetl, Arnulf (Hrsg.) 2. Auflage - November 2005, Publicis MCD Verlag, Erlangen, Chapter 19: p 498-521.
8. Grimm J, Wunder A. Molekulare Bildgebung: Stand der Forschung [Current state of molecular imaging research] *Röfo.* 2005 Mar;177(3):326-37.
9. Haberkorn U, Eisenhut M. Molecular imaging and therapy-a programme based on the development of new biomolecules. *Eur J Nucl Med Mol Imaging.* 2005; 32: 1354-9.
10. Haberkorn U, Mier W, Eisenhut M. Scintigraphic imaging of gene expression and gene transfer. *Curr Med Chem.* 2005;12(7):779-94
11. Hengerer A, Wunder A, Wagenaar D, Vija H, Shah M, Grimm J. From Genomics to Clinical Molecular Imaging. Proceedings of the IEEE 93: 819-827, 2005.
12. Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, Macke HR, Eisenhut M, Debus J, Haberkorn U. Characterization of ⁶⁸Ga-

- DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. *J Nucl Med.* 2005 May;46(5):763-9.
13. Hoffend J, Mier W, Schuhmacher J, Schmidt K, Dimitrakopoulou-Strauss A, Strauss LG, Eisenhut M, Kinscherf R, Haberkorn U. Gallium-68-DOTA-albumin as a PET blood-pool marker: experimental evaluation in vivo. *Nucl Med Biol.* 2005 Apr;32(3):287-92.
 14. Koukouraki S, Strauss LG, Georgoulas V, Schuhmacher J, Haberkorn U, Karkavitsas N, Dimitrakopoulou-Strauss A. Pharmacokinetic studies of 68Ga-DOTATOC PET in patients with metastatic neuroendocrine tumours planned for 90Y-DOTATOC therapy. *Eur J Nucl Med*: accepted.
 15. Mier W, Hoffend J, Kramer S, Schuhmacher J, Hull WE, Eisenhut M, Haberkorn U. Conjugation of DOTA using isolated phenolic active esters: the labeling and biodistribution of albumin as blood pool marker. *Bioconjug Chem* 2005;16:237-40.
 16. Mier W., R. Eritja, U. Haberkorn, Eisenhut M. Tumor selective accumulation of PNA-oligomers conjugated to a somatostatin receptor affine peptide. Proceedings of the 28th European Peptide Symposium (Eds. Flegel, Fridkin, Gilon and Slaninova) Kenes International, 2005, 166-7.
 17. Mier Walter, Keith A.N. Graham, Qin Wang, Uwe Haberkorn, and Eisenhut M. Investigations into the C-terminal modification of somatostatin analogs. Proceedings of the 28th European Peptide Symposium (Eds. Flegel, Fridkin, Gilon and Slaninova) Kenes International, 2005, 299-300.
 18. Schmidt K, Hoffend J, Altmann A, Strauss LG, Dimitrakopoulou-Strauss A, Engelhardt B, Koczan D, Peter J, Vorwald S, Eskerski H, Eisenhut M, Metz J, Kinscherf R, Haberkorn U. Transfer of the sFLT-1 gene in Morris hepatoma results in decreased growth and perfusion and induction of genes associated with stress response. *Clin Cancer Res* 2005;11:2132-40.
 19. Schuhmacher J, Zhang H, Doll J, Mäcke HR, Matys R, Hauser H, Henze M, Haberkorn U, Eisenhut M. GRP Receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a gallium-68 labeled bombesin (6-14) analog. *J Nucl Med.* 2005; 46: 691-699.
 20. Wolf M, Bauder-Wust U, Haberkorn U, Mier W, Eisenhut M. Alkylating benzamides with melanoma cytotoxicity: role of melanin, tyrosinase, intracellular pH and DNA interaction. *Melanoma Res* 2005;15(5):383-391.
 21. Wunder A, Schellenberger E, Mahmood U, Bogdanov Jr A, Müller-Ladner U, Weissleder R, Josephson L. Methotrexate Induced Accumulation of Fluorescent Annexin V In Collagen Induced Arthritis. *Mol Imaging.* 2005 Jan-Mar;4(1):1-6.
 22. Zitzmann S, Kramer S, Mier W, Mahmut M, Fleig J, Altmann A, Eisenhut M, Haberkorn U. Identification of a New Prostate-Specific Cyclic Peptide with the Bacterial FlITrx System. *J Nucl Med.* 2005 May;46(5):782-5.
 23. Zitzmann S, Mier W, Schad A, Kinscherf R, Askoxylakis V, Kramer S, Altmann A, Eisenhut M, Haberkorn U. A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy. *Clin Cancer Res.* 2005 Jan 1;11(1):139-46.
 24. Zitzmann S, Mier W, Schad A, Kinscherf R, Askoxylakis V, Krämer S, Altmann A, Eisenhut M, Haberkorn U. New Peptide (DUP-1) targets prostate carcinomas in vivo.

Proceedings of the 28th European Peptide Symposium (Eds. Flegel, Fridkin, Gilon and Slaninova) Kenes International, 2005, 449-50.

2004

1. Amthor H, Egelhof T, McKinnell I, Ladd ME, Janssen I, Weber J, Sinn H, Schrenk HH, Forsting M, Voit T, Straub V. Albumin targeting of damaged muscle fibres in the mdx mouse can be monitored by MRI. *Neuromuscul Disord.* 2004; 14: 791-796.
2. Fiehn C, Muller-Ladner U, Gay S, Krienke S, Freudenberg-Konrad S, Funk J, Ho AD, Sinn H, Wunder A. Albumin-coupled methotrexate (MTX-HSA) is a new anti-arthritis drug which acts synergistically to MTX. *Rheumatology (Oxford).* 2004 Sep;43(9):1097-1105.
3. Fiehn C, Neumann E, Wunder A, Krienke S, Gay S, Muller-Ladner U. Methotrexate (MTX) and albumin coupled with MTX (MTX-HSA) suppress synovial fibroblast invasion and cartilage degradation in vivo. *Ann Rheum Dis.* 2004; 63: 884-886.
4. Fiehn C, Wunder A, Krienke S, Max R, Ho AD, Moehler T. Lack of evidence for inhibition of angiogenesis as a central mechanism of the antiarthritic effect of methotrexate. *Rheumatol Int.* 2005 Mar;25(2):108-13.
5. Froidevaux S, Calame-Christe M, Schuhmacher J, Tanner H, Saffrich R, Henze M, Eberle AN. A gallium-labeled DOTA-alpha-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases. *J Nucl Med.* 2004; 45: 116-23.
6. Haberkorn U, Altmann A, Mier W, Eisenhut M. Impact of functional genomics and proteomics on radionuclide imaging. *Semin Nucl Med.* 2004; 34: 4-22.
7. Haberkorn U, Beuter P, Kübler W, Eskerski H, Eisenhut M, Kinscherf R, Zitzmann S, Strauss LG, Dimitrakopoulou-Strauss A, Altmann A. Iodide kinetics and dosimetry in vivo after transfer of the human sodium iodide symporter gene in rat thyroid carcinoma cells. *J Nucl Med* 2004; 45:827-833.
8. Henze M, Mohammed A, Herfarth K, Schlemmer H, Hoffner S, Haufe S, Mier W, Eisenhut M, Debus J, Haberkorn U. PET and SPECT in the detection of tumor progression in irradiated low grade astrocytomas. An ROC analysis. *J Nucl Med* 2004;45:579-586.
9. Henze M, Schuhmacher J, Dimitrakopoulou-Strauss A, Strauss LG, Mäcke HR, Eisenhut M, Haberkorn U. Exceptional increase of Somatostatin Receptor Expression in Pancreatic Neuroendocrine Tumour, visualised with ⁶⁸Ga-DOTATOC-PET. *Eur J Nucl Med* 2004;31:466.
10. Meyer GJ, Macke H, Schuhmacher J, Knapp WH, Hofmann M. ⁶⁸Ga-labelled DOTA-derivatised peptide ligands. *Eur J Nucl Med Mol Imaging.* 2004; 31: 1097-1104.
11. Mier W, Gabel D, Haberkorn U, Eisenhut M. Conjugation of the closo-borane mercaptoundeca-hydrododecaborate (BSH) to a tumour selective peptide. *Z anorgan allgem Chemie* 2004;630:1258-1262.
12. Mier W, Graham KAN, Wang Q, Krämer S, Hoffend J, Eisenhut M, Haberkorn U. Synthesis of peptide conjugated chelator oligomers for endoradiotherapy and MRT imaging. *Tetrahedron Letters* 2004;45:5433-5455.

13. Mier Walter, Johannes Hoffend, Uwe Haberkorn and Michael Eisenhut: Current strategies in tumor-targeting in „*Apoptotic pathways as target for novel therapies in cancer and other diseases.*“ edited by M. Los & S. Gibson, Kluver Academic Press (2004) ISBN: 0-387-23384-9.
14. Wang Q, Graham K, Schauer T, Fietz T, Mohammed A, Liu X, Hoffend J, Haberkorn U, Eisenhut M, Mier W. Pharmacological properties of hydrophilic and lipophilic derivatives of octreotate. *Nucl Med Biol* 2004;31:21-30.
15. Wolf M, Bauder-Wüst U, Mohammed A, Schönsiegel F, Mier W, Haberkorn U, Eisenhut M. Alkylating benzamides with melanoma cytotoxicity. *Melanoma Res* 2004;14:353-360.
16. Wunder A, Tung CH, Muller-Ladner U, Weissleder R, Mahmood U. In Vivo Imaging of Protease Activity in Arthritis: A Novel Approach for Monitoring Treatment Response. *Arthritis Rheum.* 2004; 50: 2459-2465.

2003

1. Bergter W., M. Gilbert, J. Fitschen. Prinzip einer spezifischen Entzündungshemmung und Schmerzlinderung mit [²²⁴Ra]Radiumchlorid. *Osteoporose & Rheuma Aktuell* 2 (2003) 16-19.
2. Calderon Sanchez O., A. Mohammed, W. Mier, K. Graham, J. Schuhmacher, S.O. Arndt, U. Haberkorn, R. Mocio and M. Eisenhut. 2,3,5,6-Tetrafluorophenyl N-(S-benzoylthioacetyl)glycylglycyl-p-amino-benzoate, a heterobifunctional ^{99m}Tc ligand for precomplexed antibody labeling. *Bioconjugate Chem* 2003, 14: 1209 – 1213.
3. Calderon Sanchez O., A. Mohammed, W. Mier, K. Graham, U. Haberkorn and M. Eisenhut. Synthesis, protein Synthesis, ^{99m}Tc Complexation and Protein Conjugation of 2,3,5,6-Tetrafluorophenyl N-(S-benzoylthioacetyl)glycylglycyl-p-amino-benzoate. *J. labelled Comp. Radiopharm.* 46: S247, 2003.
4. Cheng Z., A. Mahmood, D. Kramer, M. Friebe, C. Bolzati, M. Eisenhut, A. Davison, A. G. Jones. ^{99m}Tc-Labeled compounds with high melanoma affinity: Evaluation in subcutaneous and metastatic tumor models. *J. labelled Comp. Radiopharm.* 46: S400, 2003.
5. Eisenhut M., W. Mier. Radioiodination chemistry and radioiodinated compounds. In “*Handbook of Nuclear Chemistry*” (A. Vertes, S. Nagy, Z. Klencsar, Eds.). Kluver Academic Publ. Dordrecht, Boston, London. 2003, 257 – 278.
6. Graham K., Q. Wang, U. Haberkorn, M. Eisenhut, W. Mier. Synthesis of DOTATATE derivatives with an intercalating moiety. *J. labelled Comp. Radiopharm.* 46: S259, 2003.
7. Graham K., Q. Wang, U. Haberkorn, M. Eisenhut, W. Mier. Synthesis and evaluation of C-terminally modified derivatives of Tyr³-Octreotate. *J. labelled Comp. Radiopharm.* 46: S71, 2003.
8. Grimm J, Potthast A, Wunder A, Moore A. Magnetic resonance imaging of the pancreas and pancreatic tumors in a mouse orthotopic model of human cancer. *Int J Cancer.* 2003 Sep 20;106(5):806-11.
9. Haberkorn U, Kinscherf R, Kissel M, Kübler W, Mahmut M, Sieger S, Eisenhut M, Peschke P, Altmann A. Enhanced iodide transport after transfer of the human sodium

- iodide symporter gene is associated with lack of retention and low absorbed dose. *Gene Therapy* 2003; 10, 774-780.
10. Hoffend J., G. Linke, A. Mohammed, C.P. Tiefenbacher, M. Eisenhut, U. Haberkorn. $^{99m}\text{TcO}(\text{BAT-NI})$, a novel nitroimidazole tracer: in vivo uptake studies in ischemic myocardium. *Eur J Nucl Med Mol Imaging*, 2003; 30, 494-501.
 11. Kowalski J, Henze M, Schuhmacher J, Mäcke HR, Hofmann M, Haberkorn U. Evaluation of Positron Emission Tomography imaging using [^{68}Ga]-DOTA-D Phe¹-Tyr³-Octreotide in comparison to [^{111}In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. *Mol Imag Biol* 2003;5:42-48.
 12. Mahmood, Z. Cheng, H. Li, D. Kramer, M. Eisenhut, A. Davison, A. G. Jones. *N,N*-Diethylaminoethyl-benzamide-containing amine-amide-dithiol ^{99m}Tc -complexes (AADT) with melanoma affinity. *J. labelled Comp. Radiopharm.* 46: S399, 2003.
 13. Mier W, Hoffend J, Schuhmacher J, Eisenhut M, Haberkorn U. Conjugation of DOTA using isolated phenolic active esters: the labeling and biodistribution of albumin as blood pool marker. *Bioconjugate Chemistry*; submitted.
 14. Mier Walter, Ramon Eritja, Ashour Mohammed, Uwe Haberkorn, Michael Eisenhut. Peptid-PNA-Konjugate: gezielter Transport von Antisense-Oligonucleotiden in Tumoren. *Angewandte Chemie*, 42:1968-1971, 2003
 15. Popkov, M. Nádvorník, P. Kružberská, A. Lyčka, M. Eisenhut, N.M. Gillings. Asymmetric synthesis of ^{11}C -labelled α -methyl amino acids via metallocomplex chiral synthons. *J. labelled Comp. Radiopharm.* 46: S227, 2003.
 16. Repp R, Van Ojik HH, Valerius T, Groenewegen G, Wieland G, Oetzel C, Stockmeyer B, Becker W, Eisenhut M, Steininger H, Deo YM, Blijham GH, Kalden JR, Van De Winkel JG, Gramatzki M. Phase I clinical trial of the bispecific antibody MDX-H210 (anti-Fc γ RI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer. *Br J Cancer.* 2003;89:2234-43
 17. Wagner S., R. Eritja, M. Zuhayra, F. Oberdorfer, A. Mohammed, W. Mier, U. Haberkorn and M. Eisenhut. Synthesis and Properties of Radiolabeled CPTA-Oligonucleotides. *J labelled Comp Radiopharm* 46: 175-186 (2003).
 18. Weber K., H. Marx , J. Vierling , U. Wittstadt , M. Eisenhut. Electrolytic purification of [^{18}O]water. *J. labelled Comp. Radiopharm.* 46: S279, 2003.
 19. Wunder A, Grimm J, Muller-Ladner U. Molecular imaging in rheumatoid arthritis. *Z Rheumatol.* 2003;62 Suppl 2:II33-II36.
 20. Wunder A, Muller-Ladner U, Stelzer EH, Funk J, Neumann E, Stehle G, Pap T, Sinn H, Gay S, Fiehn C. Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. *J Immunol.* 2003 May 1;170(9):4793-801.
 21. Yu CS, Eisenbarth J, Runz A, Weber K, Zeisler S., Oberdorfer F. Syntheses of 5-(2-radiohaloethyl)- and 5-(2-radiohalovinyl)-2'-deoxyuridines. Novel types of radiotracer for monitoring cancer gene therapy with PET. *J. labelled Comp. Radiopharm.* 46: 421, 2003.
 22. Yu CS, Oberdorfer F. Synthesis of a novel aldehyde: 4-O-methyl-5-formylmethyl-2'-deoxyuridine. *Nucleosides Nucleotides Nucleic Acids.* 2003;22(1):71-84.

2002

1. Nader MW, Oberdorfer F. Syntheses of [carbonyl-¹¹C]2-(2-benzoylphenoxy)-N-phenylacetamide from [¹¹C]carbon monoxide by the Suzuki and the Stille reactions. *Appl Radiat Isot.* 2002 Nov;57(5):681-5.
2. Brix G; Bellemann M; Hauser H; Doll J: Ermittlung von Recovery-Koeffizienten für die Bestimmung der Arteriellen-Input-Funktion aus dynamischen PET-Messungen. *Nuklearmedizin* 41 (2002) 184-190.
3. Eisenhut M..Nuklearmedizinische Schmerztherapie.In AINS, H Beck, E Martin, J Motsch, J Schulte am Esch (Eds); Band 4 "Schmerztherapie" Georg Thieme Verlag, Stuttgart, New York, 2002: 538-553 .
4. Eisenhut M; Mohammed A; Mier W; Friebe M; Mahmood A; Jones AG; Haberkorn U: Melanoma affine ^{99m}Tc complexes comprising the N-(2-diethylaminoethyl)benzamide structure element. *J Med Chem*, 2002; 45: 5802-5805.
5. Graham K.A.N., Wang Q., Eisenhut M., Haberkorn U., Mier W. A general method for functionalising both the C- and N-terminals of Tyr³-octreotate. *Tetrahedron Letters* 43 (2002) 5021-5024.
6. Haberkorn U; Altmann A; Eisenhut M: Functional genomics and proteomics - the role of nuclear medicine. *European Journal of Nuclear Medicine* 29 (2002) 115-132.
7. Henze M; Mohammed A; Mier W; Nollert J; Rudat J; Dietz A; Eisenhut M; Haberkorn U: Pretreatment evaluation of the hypopharynx and larynx carcinoma with ¹⁸F-fluorodeoxyglucose (FDG), ¹²³(alpha)-methyl-tyrosine (IMT) and ^{99m}Tc-sestamibi (MIBI). *European Journal of Nuclear Medicine*, 29 (2002) 324-330.
8. Henze M; Mohammed A; Schlemmer H; Herfarth K; Mier W; Eisenhut M; Debus J; Haberkorn U: Detection of tumor progression in the follow-up of irradiated low grade astrocytomas: somparison of ¹²³(alpha)-methyl-L-tyrosine and ^{99m}Tc-testamibi SPECT. *Eur J Nucl Med Mol Imaging*. 2002;29:1455-61.
9. Kiessling F; Fink C; Hansen M; Bock M; Sinn H; Schrenk HH; Krix M; Egelhof T; Fusenig NE; Delorme S: Magnetic resonance imaging of nude mice with heterotransplanted high-grade squamous cell carcinomas: Use of a low-loaded, covalently bound Gd-Hsa conjugate as contrast agent with high tumor affinity. *Investigative Radiology*, 37 (2002) 193-198.
10. Kowalski J; Henze M; Schuhmacher J; Mäcke HR; Haberkorn U: Evaluation of PET imaging using ⁶⁸Ga-DOTA-D phe¹-tyr³-octreotide (DOTATOC) in comparison to (¹¹¹In)-DTPAOC (octreoscan) SPECT. First results in patients with neuroendocrine tumors. *Molecular Imaging and Biology* 5 (2002) 42-48.
11. Kremer P; Hartung G; Bauder-Wüst U; Schrenk HH; Wunder A; Heckel S; Zillmann U; Sinn H: Efficacy and tolerability of an aminopterin-albumin conjugate in tumor-bearing rats. *Anti-Cancer Drugs*, 13 (2002) 615-23.
12. Malago E., A. Mahmood, Z. Chemg, D. J. Kramer, M. Friebe, M. Eisenhut, A. Davison, A. G. Jones. Differential in vivo behaviour of Tc(V)OXO N₂S₂ complexes with melanoma affinity. In:Technetium, Rhenium and other Metals in Chemistry and Nuclear Medicine. M. Nicolini, U. Mazzi Eds., SGE Editoriali Padova, Volume 6, 2002:419-421

13. Martin S; Eisenbarth J; Wagner-Utermann U; Mier W; Henze M; Pritkow H; Haberkorn U, Eisenhut M: A new precursor for the radiosynthesis of [¹⁸F]FLT. *Nuclear Medicine and Biology* 29 (2002) 263-273.
14. Mier W., U. Haberkorn and M. Eisenhut. Editorial: [¹⁸F]FLT; Portrait of a Proliferation Marker. *Eur J Nucl Med.* 2002; 29: 165-9
15. Vajkoczy P, Farhadi M, Gaumann A, Heidenreich R, Erber R, Wunder A, Tonn JC, Menger MD, Breier G. Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. *J Clin Invest.* 2002 Mar;109(6):777-85.
16. Weigand M, Hartung G, Roboz J, Sieger S, Wolf M, Sinn H, Schrenk HH, Wiessler M, Frei E. Mode of action of methotrexate-albumin in a human T-cell leukemia line and activity against an MTX-resistant clone. *Anticancer Drug Des.* 2001 Aug-Oct;16(4-5):227-37.

2001

1. Burger AM; Hartung G; Stehle G; Sinn H; Fiebig HH: Pre-clinical evaluation of a methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts in vivo. *International Journal of Cancer*, 92 (2001) 718-724.
2. Friebe M; Mahmood A; Bolzati C; Drews A; Johannsen B; Eisenhut M; Kraemer D; Davison A; Jones AG: 99mTc oxotechnetium(V) complexes amine-amide-dithiol chelates with dialkylaminoalkyl substituents as potential diagnostic probes for malignant melanoma. *Journal of Medical Chemistry*, 44 (2001) 3132-3140.
3. Haberkorn U; Altmann A; Jiang S; Morr I; Mahmut M; Eisenhut M: Iodide uptake in human anaplastic thyroid carcinoma cells after transfer of the human thyroid peroxidase gene. *European Journal of Nuclear Medicine*, 28 (2001) 633-638.
4. Haberkorn U; Henze M; Altmann A; Jiang S; Morr I; Mahmut M; Peschke P; Debus J; Eisenhut M: Transfer of the human sodium iodide symporter gene enhances iodide uptake in hepatoma cells. *Journal of Nuclear Medicine*, 42 (2001) 317-325.
5. Haberkorn U; Kinscherf R; Krammer PH; Mier W; Eisenhut M: Investigation of a potential scintigraphic marker of apoptosis: radioiodinated Z-Val-Ala-DL-Asp(O-methyl)-fluoromethyl ketone. *Nuclear Medicine and Biology*, Oct;28(7) (2001) 793-798.
6. Henze M; Mohammed A; Mier W; Nollert J; Rudat J; Dietz A; Eisenhut M; Haberkorn U: Pretreatment evaluation of the hypopharynx and larynx carcinoma with 18F-fluorodeoxyglucose (FDG), 123(alpha)-methyl-tyrosine (IMT) and 99mTc-sestamibi (MIBI). *European Journal of Nuclear Medicine* 29 (2001) 324-330.
7. Henze M; Schuhmacher J; Hipp R; Kowalski J; Becker DW; Doll J; Mäcke HR; Debus J; Haberkorn U: PET imaging of somatostatin receptors using 68Ga-DOTA-DPhe1-Tyr3-octreotide (DOTA DOC). *Journal of Nuclear Medicine*, 42 (2001) 1053-1056.
8. Hofmann M; Maecke H; Börner AR; Weckesser E; Schöffski P; Oei ML; Schuhmacher J; Henze M; Heppeler A; Meyer GJ; Knapp WH: Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data. *European Journal of Nuclear Medicine*, 28 (2001) 1751-1757.

9. Kissel M; Peschke P; Subr V; Ulbrich K; Schuhmacher J; Debus J; Friedrich E: Synthetic macromolecular drug carriers: biodistribution of poly[(N-2-hydroxypropyl)methacrylamide] and its accumulation in solid rat tumors. *Journal of Pharmaceutical Science and Technology*, 55 (2001) 191-201.
10. Mahmood A; Friebe M; Eisenhut M; Bolzati C; Drews A; Johannsen B; Davidson A; Jones AG: Amine-amide-di-thiol (AADT)^{99m}Tc-complexes with dialkylaminoalkyl substituents as potential diagnostic probes for malignant melanoma. *Journal of labelled Comp. Radiopharm*, 44 (2001) 51-53.
11. Mier W; Eritja R; Mohammed A; Haberkorn U; Eisenhut M: Synthesis and labeling of peptide nucleic acid oligomers conjugated to octreotate. *Journal of Labelled Compounds and Radiopharmaceuticals*, Suppl. 1, 44 (2001) 954-956.
12. Mier W; Haberkorn U; Eisenhut M: Synthesis and isolation of active esters of DOTA. *Journal of Labelled Compounds and Radiopharmaceuticals*, 44 (2001) 814-816.
13. Mier W; Rossmann M; Mohammed A; Haberkorn U; Eisenhut M: 3-End-labeling procedure for phosphorothioate oligonucleotides and oligonucleotideconjugates. *Journal of Labelled Compounds and Radiopharmaceuticals*, 44 (2001) 163-166.
14. Schuhmacher J; Kaul S; Klivenyi G; Junkermann H; Magener M; Henze M; Doll J; Haberkorn U; Amelung F; Bastert G: Immunoscintigraphy with positron emission tomography: Gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti MUC1/anti-Ga chelate antibodies. *Cancer Research*, 61 (2001) 3712-3717.
15. Schuhmacher J; Klivenyi G; Kaul S; Matys R; Hauser H; Clorius JH: Pretargeting of human mammary carcinoma xenografts with bispecific anti-MUC1/anti-Ga chelate antibodies and immunoscintigraphy with PET. *Nuclear Medicine and Biology*, 28 (2001) 821-828.
16. Doll J; Werling A; Bublitz O; Hauser H; Semmler W; Brix G: Auswirkung von Aktivitäts- und Dichteverteilungen außerhalb des Gesichtsfeldes auf die Genauigkeit von 3D-PET-Messungen. In: *Medizinische Physik 2001*. Hrsg.: Welker K, Zink K. Berlin: DGMP, (2001) 345-346.
17. Kissel M; Peschke P; Subr V; Ulbrich K; Schuhmacher J; Debus J; Friedrich E: Biodistribution of charged poly(N-2-(hydroxypropyl)methacrylamide in tumor bearing rats. In: *Proc. Int'l. Symp. Control. Rel. Bioact. Mater.* Hrsg.: . San Diego, USA: , (2001) 1346-1347.
18. Roelofs TA; Grasczew G; Schneider M; Rakowsky M; Sinn H; Schlag PM: Multiphoton versus single photon excitation of photosensitizers for laser-induced fluorescence diagnosis and photodynamic therapy of cancer cells. In: *Proceedings of SPIE*. Vol. 4262, 259 - 262 (2001).